McKesson paid 1.3 times sales for Rexall DrugsMcKesson just paid 1.3 times annual sales for Rexall Drugs.
Rexall's ebitda margins were about 10% which is a bit below that of Pharmacare.
Based on this metric, CHH is currently worth about $225 million.
ITG has been accumulating recently, and with yesterday's cross now owns 2.3 million shares.
The IDA/Guradian ( McKesson) 10 year deal with CHH clearly defines an emerging pharmaceutical/ healthcare group that is well prepared for the expanded healthcare role that pharmacies are now being prepared for.
This includes many functions formerly carried out by physicians.
Buy on any manipulated weakness such as we saw yesterday.